Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Suven Life Sciences has signed a second agreement with Eli Lilly and Company to collaborate on the pre-clinical research of molecules in the therapeutic area of central nervous system disorders.
Subscribe to our email newsletter
Under the terms of the collaboration agreement, Suven will receive research funding and as well as potential discovery and development milestone payments in the range of $19 million to $23 million per candidate, and potential royalties on net sales of any products that may be successfully commercialized from the collaboration.
As per the collaboration agreement, Suven will be responsible for discovery activities related to the identification and selection of clinical candidates in the area of CNS, in close association with Lilly.
Venkat Jasti, CEO of Suven Life Sciences, said: “This collaboration leverages Suven’s small molecule drug discovery expertise with Lilly’s expertise and leadership position in CNS, with the goal of creating innovative products for unmet medical needs.”